Date: 2021-04-16

Type of information: Nomination

Compound: senior vice presidents

Company: Lexeo Therapeutics (USA-NY)

Therapeutic area: Rare diseases - Genetic diseases -Neurodegenerative diseases - Cardiovascular diseases

Type agreement: nomination

Action mechanism:



• On April 6, 2021, Lexeo Therapeutics, a clinical-stage gene therapy company, announced the continued expansion of its management team with the appointments of two
seasoned executives leading critical business functions, including Paul McCormac, Ph.D., as Senior Vice President, Technical Operations and Libbie Mansell, Ph.D., MBA, RAC, as Senior Vice President and Head of Regulatory Affairs.

Dr. McCormac is an industry expert with a proven track record in the field of gene therapy and biologics chemistry, manufacturing, and controls (CMC). Prior to joining Lexeo, he served as Medicinal Sciences Category Lead for Pfizer Rare Disease, where he among other responsibilities led gene therapy CMC and vector supply strategy for Pfizers rare disease business and research units. From 2008 to 2016, he was a product development leader in Pfizer’s
manufacturing organization, leading late-stage development and commercialization of large molecule products. Prior to joining Pfizer, he held positions in process development at Avecia Biotechnology, a leading contract manufacturer of oligonucleotide therapeutics. Dr. McCormac received his B.S. in analytical science and his Ph.D. in organic chemistry from Dublin City University and completed a post-doctoral fellowship at Queen's University Belfast.

Dr. Mansell is an experienced regulatory affairs leader whose strategic and tactical expertise in clinical research and global regulatory affairs has helped companies of all sizes progress drug candidates from discovery through post-approval. Prior to Lexeo she served as Senior Vice
President, Regulatory Affairs at Asklepios Biopharmaceuticals (AskBio). Over the past 30 years
in the biopharmaceutical industry, she has held executive positions focused on global product development, regulatory strategy and product approval. Over the course of her career, she has overseen nine product approvals for rare and/or life-threatening diseases, as well as led
regulatory and development strategy for numerous gene and cell therapies. Prior to her
experience at AskBio, Dr. Mansell has held regulatory affairs or medical affairs leadership
positions at Curis, Sigma-Tau, Genzyme and Millenium Pharmaceuticals among other companies. Dr. Mansell received her B.A. in biology and chemistry from Willamette University. She earned an MBA in finance and international business from New York University, Stern School of Business. She holds a Ph.D. in pharmacokinetics and biopharmaceutics with a minor in applied statistics from Oregon State University.

Financial terms:

Latest news:

Is general: Yes